Rituximab is now considered the first-line induction and maintenance therapy for children with severe AAV, following the success of the phase IIb global study, which tested its efficacy in 25 children with GPA and MPA [124]. The gene discussed is GYPA; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.